Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms

Journal of Immunology

Volumn 165, Issue 4, 2000, Pages 1992-2000

  Vicari, A P ^a   Ait Yahia, S ^a   Chemin, K ^a   Mueller, A ^a   Zlotnik, A ^a   Caux, C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOTACTIC FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CELLULAR IMMUNITY; COLON CARCINOMA; DENDRITIC CELL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR BLOOD FLOW;

EID: 0034663955     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.4.1992     Document Type: Article

References (58)

1. Dendritic cells and the control of immunity
2. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
3. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
4. Induction of antitumor immunity using bone marrow-generated dendritic cells
5. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
6. Dendritic cells as adjuvants for immune-mediated resistance to tumors
7. Chemokines
8. Identification and characterization of a novel β chemokine containing six conserved cysteines
9. Molecular cloning of a novel human CC chemokine secondary lymphoid- tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13
10. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7
11. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes
12. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 β are potent chemoattractants for in vitro- and in vivo-derived dendritic cells
13. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation
14. Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties
15. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
16. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7
17. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3β receptor CCR7
18. Secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes
19. A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells
20. CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKβ-11/MIP-3β/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors
21. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization
22. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
23. Ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis
24. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3
25. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
26. The role of CXC chemokines as regulators of angiogenesis
27. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
28. Chemokines and their role in tumor growth and metastasis
29. A simple quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblastic growth factor
30. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and angiogenesis
31. Single-step method of RNA isolation by acid guanidium thiocyanate- phenol-chloroform extraction
32. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
33. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas
34. Papillary carcinoma of the thyroid: Hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells
35. Specific and nonspecific immunity in the prevention of spontaneous tumours
36. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells
37. Macrophage infiltration and growth of sarcoma clones expressing different amounts of monocyte chemotactic protein/JE
38. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration
39. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations
40. Combined chemokine and cytokine gene transfer enhances antitumor immunity
41. The role of CXC chemokines in the regulation of angiogenesis in non- small cell lung cancer
42. Mig and IP-10: CXC chemokines that target lymphocytes
43. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes
44. Species specificity of the CC chemokine 6Ckine signaling through the CXC Chemokine receptor CXCR3: Human 6Ckine is not a ligand for the human or mouse CXCR3 receptors
45. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma
46. Distinct patterns and kinetics of chemokine production regulate dendritic cell function
47. Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-γ in human neutrophils
48. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ
49. Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo: Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells
50. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: Perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor
51. Distinct migration patterns of naive and effector CD8 T cells in the spleen: Correlation with CCR7 receptor expression and chemokine reactivity
52. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
53. The surface phenotype of dendritic cells purified from mouse thymus and spleen: Investigation of the CD8 expression by a subpopulation of dendritic cells
54. Decreased antigen presentation by dendritic cells in patients with breast cancer
55. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage colony- stimulating factor
56. Tumor-infiltrating dendritic cells are defective in their antigen- presenting function and inducible B7 expression in rats
57. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response
58. The CC chemokine CKβ-11/MIP-3β/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells